News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vitakine Platelet Cell Therapy from Bioparadox Improves Cardiac Function after Heart Attack, Stanford University Medical Center Study



4/8/2011 7:37:36 AM

EurekAlert! -- Menlo Park, Calif.—April 7, 2011—BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine® Platelet Cell Therapy (PCT) as a promising treatment for heart attack patients. The results of a preclinical cardiac study were presented at the 2nd Annual Translational Regenerative Medicine Forum in Washington, D.C.

Read at EurekAlert!


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES